Drugs / Recombinant Human Chorionic Gonadotrophin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01081756 | Dec 2003 → Sep 2004 | female infertility | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Chorionic Gonadotrophin | “Recombinant Human Chorionic Gonadotrophin (rhCG, Ovidrel®)” NCT01081756 ↗ |
| Known as | rhCG | “This was an open, randomized, comparative study using rhCG (Ovidrel) in the induction of final follicle maturation and early luteinization in Chinese female subjects undergoing...” NCT01081756 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Chorionic Gonadotrophin” NCT01081756 ↗ |
| Route | Intramuscular | “injection subcutaneously (s.c.) or intramuscularly (i.m.)” NCT01081756 ↗ |
| Route | Subcutaneous | “injection subcutaneously (s.c.) or intramuscularly (i.m.)” NCT01081756 ↗ |